D. E. Shaw & Co., Inc. - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 144 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$2,007,587
-56.3%
72,686
-63.6%
0.00%
-60.0%
Q1 2023$4,588,868
+123.7%
199,516
+6.1%
0.01%
+150.0%
Q4 2022$2,051,473
+70.1%
188,036
+31.4%
0.00%
+100.0%
Q3 2022$1,206,000
-18.5%
143,075
+230.5%
0.00%0.0%
Q4 2021$1,480,000
-27.9%
43,286
-62.7%
0.00%
-50.0%
Q3 2021$2,054,000
-81.6%
115,913
-53.3%
0.00%
-80.0%
Q2 2021$11,141,000
+114.0%
248,235
+23.5%
0.01%
+100.0%
Q1 2021$5,205,000
-23.4%
200,980
-40.3%
0.01%
-16.7%
Q4 2020$6,791,000
-34.2%
336,856
-36.2%
0.01%
-45.5%
Q3 2020$10,320,000
-28.1%
527,833
-35.1%
0.01%
-35.3%
Q2 2020$14,356,000
+624.7%
812,946
+189.8%
0.02%
+466.7%
Q1 2020$1,981,000
-34.7%
280,534
-34.8%
0.00%0.0%
Q4 2019$3,035,000
-23.5%
430,517
+30.4%
0.00%
-40.0%
Q3 2019$3,966,000
-17.6%
330,169
-16.9%
0.01%
-16.7%
Q2 2019$4,811,000
+48.5%
397,278
+54.1%
0.01%
+50.0%
Q1 2019$3,239,000
+2353.8%
257,728
+1211.9%
0.00%
Q4 2018$132,000
+14.8%
19,645
+75.5%
0.00%
Q3 2018$115,000
-65.9%
11,195
-77.7%
0.00%
Q2 2018$337,000
-48.2%
50,261
+60.8%
0.00%
-100.0%
Q4 2017$650,00031,2510.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$19,373,0004.95%
Bain Capital Life Sciences Investors, LLC 2,260,572$17,881,0002.10%
Finepoint Capital LP 735,126$5,815,0002.01%
Altium Capital Management LP 365,100$2,888,0001.16%
RTW INVESTMENTS, LP 4,794,499$37,924,0000.98%
Amitell Capital Pte Ltd 50,129$397,0000.90%
COWEN AND COMPANY, LLC 1,065,724$8,430,0000.81%
Tri Locum Partners LP 155,000$1,226,0000.50%
BVF INC/IL 1,106,838$8,755,0000.42%
HighVista Strategies LLC 46,459$367,0000.22%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders